# China Cardiopulmonary Exercise Testing Market > China Cardiopulmonary Exercise Testing Market Research Report By Product (CPET Metabolic Carts, Software) and By End User (Hospitals and amp; Clinics, Diagnostic Centers, Ambulatory Centers, Others) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 7.42% - **2024:** $ 84 Million - **2025:** $ 90.23 Million - **2035:** $ 184.5 Million - **Key Players:** Cardinal Health (US), Philips (NL), GE Healthcare (US), Schiller AG (CH), MediSoft (FR), COSMED (IT), KORR Medical Technologies (US), Vyaire Medical (US) **Report ID:** MRFR/HC/51057-HCR · **Pages:** 200 · **Author:** Rahul Gotadki · **Last Updated:** August 24, 2026 **URL:** https://www.marketresearchfuture.com/reports/china-cardiopulmonary-exercise-testing-market-52818 --- ## Market Summary ## **China Cardiopulmonary Exercise Testing Market Overview** As per MRFR analysis, the China Cardiopulmonary Exercise Testing Market Size was estimated at 67.5 (USD Million) in 2023. The China Cardiopulmonary Exercise Testing Market Industry is expected to grow from 72(USD Million) in 2024 to 186 (USD Million) by 2035. The China Cardiopulmonary Exercise Testing Market CAGR (growth rate) is expected to be around 9.011% during the forecast period (2025 - 2035) ## **Key China Cardiopulmonary Exercise Testing Market Trends Highlighted** The China Cardiopulmonary Exercise Testing Market is experiencing significant growth driven by an increasing focus on preventive healthcare and early disease detection. The nation has been investing in advanced healthcare technologies to address rising cardiovascular diseases, which have become a leading cause of morbidity and mortality. Such investments are supported by government policies aimed at enhancing healthcare infrastructure and promoting the adoption of modern diagnostic tools.  Moreover, the demand for cardiopulmonary exercise testing is amplified by the growing awareness among both healthcare providers and patients regarding the importance of exercise testing in assessing cardiac and pulmonary health, especially in older populations.Opportunities in the market are expanding as healthcare providers seek to integrate cardiopulmonary exercise testing into regular health check-ups and specialized care programs. There is a noticeable shift towards personalized medicine, where testing is tailored to individual health needs. This trend is further supported by emerging technologies that enhance testing accuracy and ease of use, such as portable and mobile testing devices that can be utilized in various clinical settings throughout China.  In recent times, there has been an increasing trend towards telemedicine and remote monitoring solutions in China, particularly influenced by the COVID-19 pandemic.This shift has prompted the healthcare sector to adopt new methodologies, including remote cardiopulmonary exercise testing, which allows for comprehensive evaluations of patients while also adhering to social distancing measures. Furthermore, research and educational initiatives regarding the benefits of exercise testing are being promoted by various health authorities, thereby increasing the familiarity and acceptance of these tests among the Chinese populace. As the market evolves, the alignment of healthcare services with emerging trends will play a critical role in shaping the future landscape of cardiopulmonary exercise testing in China. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **China Cardiopulmonary Exercise Testing Market Drivers** ### **Increasing Prevalence of Cardiovascular Diseases** The growing prevalence of cardiovascular disorders in China is a key driver of the China Cardiopulmonary Exercise Testing Market Industry. According to the National Health Commission of the People's Republic of China, cardiovascular disorders account for almost 40% of all fatalities in the country. With an aging population and changing lifestyles, the prevalence of these illnesses is expected to rise dramatically. According to the China Cardiovascular Health Report, around 330 million people in China suffer from cardiovascular disorders.  Organizations such as the Chinese Preventive Medicine Association emphasize the importance of early detection and management techniques, including cardiopulmonary exercise testing. As healthcare professionals seek effective diagnostic tools, there is an increased emphasis on preventative health measures, which promotes market growth. ### **Government Initiatives to Promote Preventive Healthcare** Chinese government policies increasingly prioritize preventive healthcare, which directly influences the development of the China Cardiopulmonary Exercise Testing Market Industry. The State Council of the People's Republic of China has launched several initiatives aimed at enhancing the prevention and treatment of chronic diseases, with substantial investments funneled into healthcare infrastructure. The Healthy China 2030 initiative emphasizes the need for regular health screenings and early interventions. These policies not only underscore the importance of cardiopulmonary exercise testing but also encourage healthcare facilities to adopt advanced diagnostic technologies. Consequently, this proactive approach from the government is expected to enhance the demand for cardiopulmonary exercise testing services. ### **Technological Advancements in Cardiopulmonary Exercise Testing Equipment** Innovations in medical technology significantly boost the China Cardiopulmonary Exercise Testing Market Industry. Recent developments in non-invasive testing methods have made cardiopulmonary exercise testing more accurate and user-friendly. Prominent companies such as GE Healthcare and InstrumenTation Laboratory have introduced next-generation exercise testing equipment that provides real-time data analysis, improving diagnostic accuracy.  According to data from the China National Intellectual Property Administration, the number of patents related to cardiopulmonary exercise equipment increased by over 30% from 2018 to 2022, reflecting a growing innovation trend.This surge in advancements allows healthcare providers in China to offer better diagnostic services, thus driving the market growth. ## **China Cardiopulmonary Exercise Testing Market Segment Insights** ### **Cardiopulmonary Exercise Testing Market Product Insights** The China Cardiopulmonary Exercise Testing Market is primarily driven by the need for accurate evaluation of cardiovascular and pulmonary function, and the Product segment plays a crucial role in fulfilling this demand. Within this segment, CPET Metabolic Carts are essential tools for healthcare providers, enabling them to conduct comprehensive exercise testing. These carts gather detailed metabolic data during physical exertion, making them vital for diagnosing various health conditions and tailoring rehabilitation protocols. The significance of CPET Metabolic Carts in the clinical setting lies in their ability to provide real-time data that informs treatment decisions and improves patient outcomes. Transitioning to Software solutions, these applications enhance the functionality of the testing equipment by facilitating data analysis, patient management, and reporting. As healthcare facilities in China increasingly prioritize technological integration, the demand for sophisticated software that complements physical testing equipment continues to grow. This synergy between CPET Metabolic Carts and Software is pivotal, as it not only streamlines workflow but also ensures accuracy in test results, thereby fostering enhancements in operational efficiency and patient care. Thus, the ongoing advancements in both areas signal a robust future for the China Cardiopulmonary Exercise Testing Market, especially in light of emerging trends in digital health and personalized medicine. Given the supportive policies from the Chinese government regarding healthcare modernization and an aging population that requires improved cardio-pulmonary health solutions, these product offerings are set to experience significant growth in the coming years.  The combination of innovative technology and dedicated clinical applications in this segment positions it as a cornerstone of the broader market landscape in China. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Cardiopulmonary Exercise Testing Market End User Insights** The China Cardiopulmonary Exercise Testing Market showcases a diverse range of End Users, primarily comprising Hospitals and Clinics, Diagnostic Centers, Ambulatory Centers, and Others, each contributing distinctly to the overall healthcare landscape. Hospitals and Clinics play a pivotal role, leveraging advanced cardiopulmonary exercise testing for comprehensive patient assessments and enhancing clinical decision-making. Diagnostic Centers serve as critical facilities that provide specialized testing, driving the growing demand for accurate diagnostic tools within the healthcare system. Ambulatory Centers are increasingly gaining traction due to their convenience, offering patients easy access to necessary testing without prolonged hospital stays, which aligns well with the rising preference for outpatient care. Additionally, the Other segment may include rehabilitation centers and research institutions, which complement the overall market by pushing for innovation in testing methodologies. The increasing prevalence of respiratory and cardiovascular diseases in China continues to elevate the importance of these End Users, driving the need for effective exercise testing solutions across various clinical environments. With a significant focus on improving patient outcomes and tailoring treatments, the End User segment remains crucial for the ongoing growth and development of the China Cardiopulmonary Exercise Testing Market. ## **China Cardiopulmonary Exercise Testing Market Key Players and Competitive Insights** The China Cardiopulmonary Exercise Testing Market has been experiencing significant growth, fueled by increasing awareness of cardiovascular health, a rising geriatric population, and advancements in medical technology. A surge in the demand for effective diagnostic tests that provide insights into an individual's cardiovascular and respiratory fitness has prompted various industry players to invest in this sector. In this highly competitive landscape, companies are striving to enhance their operational efficiency and product offerings while focusing on innovation to meet the evolving needs of healthcare practitioners and patients alike.  With the integration of advanced technologies and the growing emphasis on preventive healthcare, the market dynamics are continually transforming, leading to varied opportunities and challenges for stakeholders involved.Cosmed has established a strong foothold in the China Cardiopulmonary Exercise Testing Market, recognized for its innovative technologies and reliable solutions in metabolic and cardiopulmonary testing. The company’s reputation is built on its commitment to quality, precision, and user-friendly operational features, which cater to healthcare providers seeking to enhance patient care.  Cosmed has focused its efforts on providing tailored products that facilitate accurate diagnostics and monitoring, assisting healthcare professionals in their assessments of patients' health conditions. Its wide range of cardiopulmonary testing equipment has proven useful in various clinical applications, promoting the company's position as a leader in this niche market segment. The firm's ability to leverage advanced research and development while prioritizing customer needs further reinforces its competitive advantage in China.Cardiovascular Systems operates within the China Cardiopulmonary Exercise Testing Market with a focus on delivering a comprehensive suite of products designed for cardiovascular assessment and intervention.  The company's portfolio includes various tools and technologies aimed at enhancing diagnostic capabilities in cardiopulmonary health. Cardiovascular Systems has made notable strides in establishing partnerships and collaborations within the region, strengthening its market reach and operational impact. The company’s strengths lie in its innovative approach to product development and commitment to improving patient outcomes through high-quality solutions. Additionally, Cardiovascular Systems has engaged in strategic mergers and acquisitions, allowing it to expand its service offerings and enhance its technological capabilities within China, ensuring it remains competitive amidst a rapidly evolving healthcare landscape. ### **Key Companies in the China Cardiopulmonary Exercise Testing Market Include** - [Cosmed](https://www.cosmed.com/en/resources/science/95-cardio-pulmonary-exercise-test/) - Cardiovascular Systems - Roche - Welch Allyn - MediServe - Bodenheim - Edan Instruments - InBody - Philips - Kardiovize - GE Healthcare - Zanmed - Schiller AG - Cortex Biophysik GmbH - Mortara Instrument ## **China Cardiopulmonary Exercise Testing Market Industry Developments** The China Cardiopulmonary Exercise Testing Market has experienced significant developments recently. As of September 2023, several companies, including Cosmed and GE Healthcare, are expanding their product portfolios to enhance testing accuracy and patient monitoring capabilities. Concurrently, Edan Instruments has reported advancements in its technology, focusing on integrating AI into cardiopulmonary testing systems. The market has seen an increased investment, leading to a growth in valuation across key players, including Philips and Roche, which reflects the rising demand for advanced diagnostic solutions.  In terms of corporate movements, Cardiovascular Systems has successfully acquired a local startup to bolster its research and development efforts in China, announced in August 2023. Furthermore, competitive strategies among companies like Mortara Instrument and Schiller AG are anticipated to elevate market standards, ensuring better healthcare delivery. The increased emphasis on preventative healthcare in China has propelled the adoption of cardiopulmonary exercise testing devices, indicating a trend toward more sophisticated healthcare infrastructure and an expanding market footprint for these companies. ## **China Cardiopulmonary Exercise Testing Market Segmentation Insights** ### **Cardiopulmonary Exercise Testing Market Product****Outlook** - CPET Metabolic Carts - Software ### **Cardiopulmonary Exercise Testing Market End User****Outlook ** - Hospitals & Clinics - Diagnostic Centers - Ambulatory Centers - Others ## Market Drivers ### Growing Geriatric Population The demographic shift towards an older population in China is a crucial factor driving the cardiopulmonary exercise-testing market. As individuals age, the risk of developing cardiovascular and pulmonary diseases escalates, necessitating regular health assessments. The geriatric population is projected to reach over 400 million by 2040, creating a substantial demand for effective diagnostic tools like cardiopulmonary exercise testing. This testing method is particularly valuable for older adults, as it helps in assessing their physical capacity and guiding rehabilitation efforts. Consequently, the cardiopulmonary exercise-testing market is likely to see a robust growth trajectory, with an anticipated annual growth rate of around 7% in the coming years. ### Advancements in Medical Technology Technological innovations in medical devices and testing methodologies are propelling the cardiopulmonary exercise-testing market forward. The introduction of more sophisticated and user-friendly equipment has made cardiopulmonary exercise testing more efficient and accurate. Innovations such as portable testing devices and advanced software for data analysis are enhancing the testing experience for both patients and healthcare providers. These advancements not only improve diagnostic accuracy but also facilitate remote monitoring, which is becoming increasingly important in modern healthcare. As a result, the market is expected to grow, with a projected increase in revenue of approximately $50 million by 2026, driven by these technological enhancements. ### Government Initiatives and Funding Government initiatives aimed at improving healthcare infrastructure in China are significantly influencing the cardiopulmonary exercise-testing market. The Chinese government has been investing heavily in healthcare reforms, which include funding for advanced diagnostic technologies. This financial support is likely to enhance the availability and accessibility of cardiopulmonary exercise testing in hospitals and clinics across the country. Furthermore, public health campaigns promoting cardiovascular health are expected to increase awareness and demand for such testing. As a result, the market may experience a boost, with estimates suggesting an increase in market size by over $100 million by 2027 due to these initiatives. ### Increased Focus on Preventive Healthcare The shift towards preventive healthcare in China is significantly impacting the cardiopulmonary exercise-testing market. With rising healthcare costs and a growing emphasis on early intervention, more individuals are seeking preventive measures to maintain their health. Cardiopulmonary exercise testing serves as a proactive approach to assess cardiovascular and pulmonary health, allowing for early detection of potential issues. This trend is supported by healthcare policies that encourage regular health screenings and assessments. As awareness of the benefits of preventive healthcare continues to grow, the cardiopulmonary exercise-testing market is likely to expand, with estimates suggesting a market growth of around 6% annually over the next few years. ### Rising Incidence of Cardiovascular Diseases The increasing prevalence of cardiovascular diseases in China is a primary driver for the cardiopulmonary exercise-testing market. According to health statistics, cardiovascular diseases account for a significant portion of mortality rates, prompting healthcare providers to seek effective diagnostic tools. The demand for early detection and management of these conditions has led to a surge in the utilization of cardiopulmonary exercise testing. This testing method provides critical insights into a patient's cardiovascular and pulmonary function, enabling tailored treatment plans. As the population ages and lifestyle-related health issues become more common, the cardiopulmonary exercise-testing market is expected to expand, with projections indicating a growth rate of approximately 8% annually over the next five years. ## Future Outlook The [Cardiopulmonary Exercise Testing Market](https://www.marketresearchfuture.com/reports/cardiopulmonary-exercise-testing-market-6626) is projected to grow at a 7.42% CAGR from 2025 to 2035, driven by technological advancements and increasing health awareness. **New opportunities:** - Development of portable testing devices for home use - Integration of AI for personalized exercise prescriptions - Expansion of telehealth services for remote patient monitoring By 2035, the market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Product Type: CPET metabolic carts (Largest) vs. software (Fastest-Growing) In the China cardiopulmonary exercise-testing market, the CPET metabolic carts hold the largest market share, reflecting their widespread adoption in clinical and fitness environments. This category has become a staple for accurate measurement of cardiovascular and pulmonary functions, leading to its dominance in the market. Conversely, software solutions are gaining traction, with a growing share as healthcare facilities increasingly integrate technology into exercise testing protocols, driven by the demand for improved data management and analysis. Growth trends showcase a shift towards advanced software systems that provide real-time data analytics and patient monitoring, appealing to healthcare providers seeking efficiency. The rise in telehealth and remote monitoring capabilities has further accelerated software adoption, as more clinicians leverage these tools for enhanced patient engagement and outcomes. This dual dynamic of established hardware and emerging software illustrates the evolving landscape of the cardiopulmonary exercise-testing ecosystem. CPET metabolic carts (Dominant) vs. software (Emerging) CPET metabolic carts are characterized by their robust design, enabling comprehensive analysis of a patient's cardiopulmonary responses during exercise. These devices are essential in clinical settings for diagnosing various heart and lung conditions, thus maintaining their position as the dominant product in the market. Emerging software solutions, on the other hand, focus on providing integrated platforms that enhance data visualization, storage, and patient tracking. This innovation is crucial for medical professionals in adapting to technology-driven healthcare environments. While CPET metabolic carts continue to be indispensable, the software segment is rapidly evolving, driven by digital health trends, focusing on interoperability and user-friendly interfaces to streamline clinical processes. ### By End User: Hospitals & Clinics (Largest) vs. Diagnostic Centers (Fastest-Growing) In the China cardiopulmonary exercise-testing market, the distribution of market share among end user segments reveals a significant dominance of hospitals and clinics, which cater to a wide range of patient needs and facilitate extensive testing services. Diagnostic centers are emerging rapidly, focusing on specialized tests, thus capturing an increasing share as they meet the growing healthcare demands. Growth trends in this segment are primarily driven by an increase in chronic diseases and the need for advanced diagnostic tools. Hospitals and clinics continue to serve as the primary endpoints for these services, while diagnostic centers are capitalizing on technological advancements and the rise in outpatient services. This shift indicates a trend towards more accessible and efficient testing solutions, fostering competition and innovation within the market. Hospitals & Clinics (Dominant) vs. Diagnostic Centers (Emerging) Hospitals and clinics are characterized by their extensive infrastructure and established presence in the healthcare system. They provide comprehensive cardiopulmonary exercise-testing services to a vast patient population. Their dominant position stems from the ability to offer integrated care and access to specialized resources. In contrast, diagnostic centers are emerging as key players by focusing on niche testing services and employing state-of-the-art technology. These centers attract patients seeking specialized tests and faster results, positioning themselves as innovative alternatives to traditional facilities. As the demand for efficient healthcare solutions grows, both segments are expected to evolve, with diagnostic centers potentially capturing a larger market share in the coming years. ## Competitive Benchmarking The cardiopulmonary exercise-testing market is characterized by a dynamic competitive landscape, driven by increasing demand for advanced diagnostic tools and a growing emphasis on personalized medicine. Key players such as Cardinal Health (US), Philips (NL), and GE Healthcare (US) are strategically positioned to leverage their technological expertise and extensive distribution networks. Cardinal Health (US) focuses on enhancing its product offerings through innovation and strategic partnerships, while Philips (NL) emphasizes digital transformation and integrated solutions to improve patient outcomes. GE Healthcare (US) is actively pursuing regional expansion and collaborations to strengthen its market presence, collectively shaping a competitive environment that is increasingly focused on technological advancement and patient-centric solutions.In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to enhance operational efficiency and reduce costs. The market appears moderately fragmented, with a mix of established players and emerging companies vying for market share. The collective influence of these key players is significant, as they drive innovation and set industry standards, thereby influencing the overall market structure. In October Philips (NL) announced the launch of a new cloud-based cardiopulmonary exercise-testing platform designed to streamline data management and enhance patient monitoring capabilities. This strategic move is likely to position Philips as a leader in digital health solutions, catering to the growing demand for remote patient management and real-time data analytics. The integration of cloud technology into cardiopulmonary testing could significantly improve clinical workflows and patient outcomes. In September GE Healthcare (US) expanded its partnership with a leading Chinese healthcare provider to enhance the accessibility of its cardiopulmonary exercise-testing equipment across the region. This collaboration is expected to facilitate the introduction of advanced diagnostic tools in underserved areas, thereby addressing critical healthcare gaps. Such strategic alliances not only bolster GE Healthcare's market presence but also align with the broader trend of increasing healthcare accessibility in China. In August Cardinal Health (US) acquired a local medical device manufacturer to strengthen its supply chain and enhance its product portfolio in the cardiopulmonary exercise-testing segment. This acquisition is indicative of Cardinal Health's commitment to expanding its operational capabilities and ensuring a reliable supply of innovative products. By integrating local expertise, the company aims to better meet the specific needs of the Chinese market, thereby enhancing its competitive edge. As of November the competitive trends in the cardiopulmonary exercise-testing market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI). Strategic alliances are becoming more prevalent, as companies recognize the importance of collaboration in driving innovation and enhancing service delivery. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on technological innovation, reliability of supply chains, and the ability to deliver personalized healthcare solutions. This shift underscores the necessity for companies to adapt and innovate continuously in order to maintain a competitive advantage. ## Recent News & Developments The China Cardiopulmonary Exercise Testing Market has experienced significant developments recently. As of September 2023, several companies, including Cosmed and GE Healthcare, are expanding their product portfolios to enhance testing accuracy and patient monitoring capabilities. Concurrently, Edan Instruments has reported advancements in its technology, focusing on integrating AI into cardiopulmonary testing systems. The market has seen an increased investment, leading to a growth in valuation across key players, including Philips and Roche, which reflects the rising demand for advanced diagnostic solutions.  In terms of corporate movements, Cardiovascular Systems has successfully acquired a local startup to bolster its research and development efforts in China, announced in August 2023. Furthermore, competitive strategies among companies like Mortara Instrument and Schiller AG are anticipated to elevate market standards, ensuring better healthcare delivery. The increased emphasis on preventative healthcare in China has propelled the adoption of cardiopulmonary exercise testing devices, indicating a trend toward more sophisticated healthcare infrastructure and an expanding market footprint for these companies. ## Report Scope | MARKET SIZE 2024 | 84.0(USD Million) | | --- | --- | | MARKET SIZE 2025 | 90.23(USD Million) | | MARKET SIZE 2035 | 184.5(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.42% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Cardinal Health (US), Philips (NL), GE Healthcare (US), Schiller AG (CH), MediSoft (FR), COSMED (IT), KORR Medical Technologies (US), Vyaire Medical (US) | | Segments Covered | Product Type, End User | | Key Market Opportunities | Integration of advanced wearable technology enhances patient monitoring in the cardiopulmonary exercise-testing market. | | Key Market Dynamics | Rising demand for advanced cardiopulmonary exercise-testing technologies driven by regulatory changes and increasing health awareness. | | Countries Covered | China | ## Frequently Asked Questions **Q: What is the current valuation of the China cardiopulmonary exercise-testing market as of 2024?** A: The market valuation was $84.0 Million in 2024. **Q: What is the projected market valuation for the China cardiopulmonary exercise-testing market in 2035?** A: The projected valuation for 2035 is $184.5 Million. **Q: What is the expected CAGR for the China cardiopulmonary exercise-testing market during the forecast period 2025 - 2035?** A: The expected CAGR during this period is 7.42%. **Q: Which product types dominate the China cardiopulmonary exercise-testing market?** A: The market includes product types such as CPET metabolic carts, valued between $60.0 Million and $130.0 Million, and software, valued between $24.0 Million and $54.5 Million. **Q: What are the primary end-user segments in the China cardiopulmonary exercise-testing market?** A: Key end-user segments include Hospitals & Clinics, valued between $40.0 Million and $90.0 Million, and Diagnostic Centers, valued between $20.0 Million and $45.0 Million. **Q: Who are the key players in the China cardiopulmonary exercise-testing market?** A: Key players include Cardinal Health, Philips, GE Healthcare, Schiller AG, MediSoft, COSMED, KORR Medical Technologies, and Vyaire Medical. **Q: How does the market size in 2035 compare to that in 2024?** A: The market is expected to grow from $84.0 Million in 2024 to $184.5 Million in 2035. **Q: What factors might contribute to the growth of the China cardiopulmonary exercise-testing market?** A: Factors contributing to growth may include advancements in technology and increasing demand for diagnostic services. **Q: What is the significance of the CPET metabolic carts segment in the market?** A: The CPET metabolic carts segment is crucial, with a valuation range of $60.0 Million to $130.0 Million, indicating strong market interest. **Q: How are ambulatory centers positioned within the China cardiopulmonary exercise-testing market?** A: Ambulatory centers are valued between $15.0 Million and $35.0 Million, reflecting their role as a growing segment in the market. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/china-cardiopulmonary-exercise-testing-market-52818*